Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation

Reproductive BioMedicine Online

Volumn 18, Issue 1, 2009, Pages 67-72

  Bahçeci, Mustafa ^a   Ulug, Ulun ^a   Erden, Halit Firat ^a   Tosun, Suleyman ^a   Çiray, Nadir ^a  

^a German Hospital in Istanbul   (Turkey)

Author keywords

Embryo; Endometrium; Frozen; GnRH antagonist

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; EMBRYO; EMBRYO TRANSFER; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FREEZE THAWING; HUMAN; HUMAN TISSUE; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MALE; NIDATION; OOCYTE CLEAVAGE; OOCYTE RETRIEVAL; OUTCOMES RESEARCH; OVULATION INDUCTION; PREGNANCY RATE; RETROSPECTIVE STUDY;

EID: 58649084845     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60426-9     Document Type: Article

References (29)

1. Al-Inany HG, Abou-Setta AM, Aboulghar M 2007 Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reproductive BioMedicine Online 14, 640-649.
2. Bilotas M, Barañao RI, Buquet R et al. 2007 Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls. Human Reproduction 22, 644-653.
3. Chou CS, Tai CJ, MacCalman CD, Leung PC 2003a Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual stromal cells in vitro. Journal of Clinical Endocrinology and Metabolism 88, 680-688.
4. Chou CS, Zhu H, MacCalman CD, Leung PC 2003b Regulatory effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the levels of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinases-1 in primary cultures of human extravillous cytotrophoblasts. Journal of Clinical Endocrinology and Metabolism 88, 4781-4790.
5. Chou CS, Zhu H, Shalev E et al. 2002 The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. Journal of Clinical Endocrinology and Metabolism 87, 5594-5603.
6. Cunha-Filho JS, Lemos N, Stein N et al. 2005 Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in-vitro fertilization with a gonadotropin-releasing hormone antagonist. Fertility and Sterility 83, 902-907.
7. Eldar-Geva T, Zylber-Haran E, Babayof R et al. 2007 Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/ GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation. Reproductive BioMedicine Online 14, 148-154.
8. Griesinger G, Felberbaum R, Diedrich K 2005 GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Human Reproduction 20, 2373-2375.
9. Gründker C, Günthert AR, Millar RP, Emons G 2002 Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. Journal of Clinical Endocrinology and Metabolism 87, 1427-1430.
10. Guzeloglu-Kayisli O, Basar M, Arici A 2007 Basic aspects of implantation. Reproductive BioMedicine Online 15, 728-739.
11. Hernandez ER 2000 Embryo implantation and GnRH antagonists: embryo implantation: the rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
12. Hughes EG, Fedorkow DM, Daya S et al. 1992 The routine use of gonadotropin-releasing hormone agonists prior to in-vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 58, 888-896.
13. Kol S, Lightman A, Hillensjo T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
14. Kolibianakis E, Bourgain C, Albano C et al. 2002 Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertility and Sterility 78, 1025-1029.
15. Loumaye E 1990 The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Human Reproduction 5, 357-376.
16. Luo X, Ding L, Chegini N 2004 Gonadotropin-releasing hormone and TGF-beta activate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells. American Journal of Physiology Endocrinology and Metabolism 287, E991-E1001.
17. Medved R, Virant-Klun I, Meden-Vrtovec H, Tomazevic T 2006 Outcome of frozen-thawed blastocysts derived from gonadotropin releasing hormone agonist or antagonist cycles. Journal of Assisted Reproduction and Genetics 23, 275-279.
18. Meresman GF, Bilotas M, Buquet RA et al. 2003 Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertility and Sterility 80 (Suppl. 2), 702-707.
19. Raga F, Casan EM, Kruessel J et al. 1999 The role of gonadotropin releasing hormone in murine preimplantation embryonic development. Endocrinology 140, 3705-3712.
20. Ruan HC, Zhu XM, Luo Q et al. 2006 Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Human Reproduction 1, 2521-2529.
21. Saadat P, Boostanfar R, Slater CC et al. 2004 Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertility and Sterility 82, 167-171.
22. Seelig AS, Al-Hasani S, Katalinic A et al. 2002 Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertility and Sterility 77, 472-475.
23. Simon C, Oberyé J, Bellver J et al. 2005 Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Human Reproduction 20, 3318-3327.
24. Sirayapiwat P, Suwajanakorn S, Triratanachat S, Niruthisard S 2007 The effects of GnRH antagonist on the endometrium of normally menstruating women. Journal of Assisted Reproduction and Genetics 24, 579-586.
25. Smitz J, Van Den Abbeel E, Bollen N et al. 1992 The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women. Human Reproduction 7, 1098-1102.
26. Ulug U, Turan E, Tosun SB et al. 2007 Comparison of preovulatory follicular concentrations of epidermal growth factor, insulin like growth factor-1, and inhibins A and B in women undergoing assisted conception with gonadotropin releasing hormone agonists and antagonists. Fertility and Sterility 87, 995-998.
27. Vani S, McDonald SE, Williams AR et al. 2007 Mid-luteal endometrial intracrinology following controlled ovarian hyperstimulation involving use of a gonadotrophin releasing hormone antagonist. Human Reproduction 22, 2981-2991.
28. Vlahos NF, Lipari CW, Bankowski B et al. 2006 Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in-vitro fertilization. Journal of Clinical Endocrinology and Metabolism 91, 4043-4049.
29. Zikopoulos K, Kolibianakis EM, Camus M et al. 2004 Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertility and Sterility 81, 473-475.